Form 8-K FIVE PRIME THERAPEUTICS For: Mar 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- Lula, Brazil's iconic working class president, wins historic fourth term in dramatic comeback
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
- Accenture shares fall on insider sales and analyst downgrade
- Wall Street closes lower to end rocky week
- Credo Technology shares fall on competition concerns
Five Prime Therapeutics (FPRX) Posts Q4 Loss of 55c/Share
March 17, 2015 4:26 PM EDTFive Prime Therapeutics (NASDAQ: FPRX) reported Q4 EPS of ($0.55), $0.45 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $4.65 million versus the consensus estimate of $12.4 million.
For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.
... More


